Log in to search using one of your social media accounts:

 

FDA OKs First Adjuvant Treatment for Kidney Cancer FDA OKs First Adjuvant Treatment for Kidney Cancer
Sunitinib is now approved for use after surgery in renal cell carcinoma patients who are at high risk for disease recurrence.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Pfizer receives FDA approval for SUTENT ® (sunitinib malate) as first and only adjuvant treatment for adult patients at high risk of recurrent renal cell carcinoma
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney). (Source: World Pharma News)
Source: World Pharma News - November 16, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Cancer treatment response may be affected by gut bacteria
Conclusion This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. We don't know what the conditions that required antibiotic treatment were and whether these could have affected the response to immunotherapy. We don't know whether the antibiotics themselves influenced how well the immunotherapy worked, or whether it was their effect on gut bacteria. We also don't know whether having high levels of part...
Source: NHS News Feed - November 3, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Study reveals complex biology, gender differences, in kidney cancer
(University of Rochester Medical Center) A new study is believed to be the first to describe the unique role of androgens in kidney cancer, and it suggests that a new approach to treatment, targeting the androgen receptor (AR), is worth further investigation. The study shows that in renal cell carcinoma androgen signaling can either stimulate or suppress tumor cells' movement and invasion to different locations in the body. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 13, 2017 Category: Cancer & Oncology Source Type: news

Sunitinib Has No Survival Benefit in Renal-cell Carcinoma, May Limit Late Recurrence Sunitinib Has No Survival Benefit in Renal-cell Carcinoma, May Limit Late Recurrence
Adjuvant treatment of renal-cell carcinoma (RCC) after nephrectomy with sunitinib has produced no increase in overall survival, but the treatment results in less distant disease recurrence and a higher rate of disease-free survival, according to the latest data from the S-TRAC study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 5, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Eisai reports positive data from Phase Ib/II study of lenvatinib for RCC
Eisai has reported positive interim results from a Phase Ib/II clinical trial (Study 111) of Kisplyx (lenvatinib) in combination with Merck ’s anti-PD-1 therapy pembrolizumab (Keytruda) to treat patients with advanced renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 11, 2017 Category: Pharmaceuticals Source Type: news

BMS ’ Phase III combination trial for renal cell carcinoma meets endpoints
Bristol-Myers Squibb (BMS) has reported positive results from its Phase III clinical trial (CheckMate -214) of Opdivo and Yervoy combination for renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news

European Commission licences EUSA ’s advanced RCC treatment fotivda
Jazz Pharmaceuticals subsidiary EUSA Pharma ’s fotivda (tivozanib) has been licensed by the European Commission (EC) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 30, 2017 Category: Pharmaceuticals Source Type: news

Translocation Renal Cell Carcinoma: An Update
Microphthalmia-associated transcription (MiT) family translocation renal cell carcinoma (tRCC) comprises Xp11 tRCC and t(6;11) RCC.08/29/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2017 Category: Urology & Nephrology Source Type: news

AVEO Pharma stock rises 6% after cancer drug gets approved
The drug, Fotivda, was approved for adults with advanced renal cell carcinoma -- the most common type of kidney cancer08/29/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2017 Category: Urology & Nephrology Source Type: news

Longer Telomeres Linked to Renal-cell Carcinoma Risk Longer Telomeres Linked to Renal-cell Carcinoma Risk
Genetic variants that predispose individuals to longer telomere length appear to be associated with an increased risk of renal-cell carcinoma (RCC), according to results from a genome-wide association studies (GWAS) database analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 22, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Exelixis Submits sNDA for Kidney Cancer Drug
The sNDA submission was based on positive results from phase II trial, CABOSUN, in patients with previously untreated advanced RCC with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).08/20/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 19, 2017 Category: Urology & Nephrology Source Type: news

Bristol-Myers Squibb shares slip as kidney cancer drug trial falls short of goal
...use of the drugs Opdivo and Yervoy showed that renal cell carcinoma patients responded better to the combination versus those taking the drug sunitinib, survival rates without progression of the disease did not reach statistical significance.08/16/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 16, 2017 Category: Urology & Nephrology Source Type: news

BMS Phase III ’s combination trial for RCC meets one co-primary endpoint
Bristol-Myers Squibb (BMS) has reported top-line results from the Phase III CheckMate -214 clinical trial of Opdivo (nivolumab) and Yervoy (ipilimumab) combination to treat advanced or metastatic renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 15, 2017 Category: Pharmaceuticals Source Type: news

Bristol-Myers Squibb announces topline results from CheckMate -214
Bristol-Myers Squibb Company (NYSE: BMY) announced topline results today from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus sunitinib in intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma. (Source: World Pharma News)
Source: World Pharma News - August 15, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Positive Surgical Margins in RCC More Common Among African Americans
African American patients with localized renal cell carcinoma who underwent robotic partial nephrectomy were at an increased risk for positive surgical margins compared with white patients. (Source: CancerNetwork)
Source: CancerNetwork - August 14, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Immunicum starts enrolment in US for Phase II oncology trial
Swedish biopharmaceutical firm Immunicum has started patient enrolment in the US for the ongoing Phase II MERECA clinical trial of its drug candidate ilixadencel to treat renal cell carcinoma. (Source: Drug Development Technology)
Source: Drug Development Technology - August 10, 2017 Category: Pharmaceuticals Source Type: news

Calithera begins Phase II trial of CB-839 to treat renal cell carcinoma
Pharmaceutical firm Calithera Biosciences has begun a Phase II clinical trial of CB-839 in combination with Afinitor (everolimus) ‎ for the treatment of patients with renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 7, 2017 Category: Pharmaceuticals Source Type: news

Second-Line Therapy Options in Metastatic Renal Cell Carcinoma
This video reviews the various treatment options for metastatic renal cell carcinoma in the second-line setting, including considerations for different toxicity profiles. (Source: CancerNetwork)
Source: CancerNetwork - August 1, 2017 Category: Cancer & Oncology Authors: Neeraj Agarwal, MD Tags: Renal Cell Carcinoma Videos Genitourinary Cancers Source Type: news

First-Line Treatment of Metastatic Renal Cell Carcinoma
This video reviews the first-line treatment of metastatic renal cell carcinoma, including for those patients who are ineligible for interleukin-2. (Source: CancerNetwork)
Source: CancerNetwork - August 1, 2017 Category: Cancer & Oncology Authors: Neeraj Agarwal, MD Tags: Renal Cell Carcinoma Videos Genitourinary Cancers Source Type: news

Drug combination shows better tolerance and effectiveness in metastatic renal cell cancer
A new cooperative research study including Norris Cotton Cancer Center's Lionel Lewis, MB BCh, MD, finds that nivolumab plus ipilimumab therapy demonstrated manageable safety, notable antitumor activity, and durable responses with promising long term overall survival in patients with metastatic renal cell cancer (mRCC). (Source: World Pharma News)
Source: World Pharma News - July 27, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Drug combination more effective in metastatic renal cell cancer
Researchers report they have identified new drug combination is more effective and better tolerated in the treatment of metastatic renal cell cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 26, 2017 Category: Consumer Health News Source Type: news

Immunotherapy Combination in Metastatic RCC Proves Effective
Patients with metastatic renal cell carcinoma had durable responses and manageable safety when treated with the combination of nivolumab and ipilimumab. (Source: CancerNetwork)
Source: CancerNetwork - July 26, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Drug combination shows better tolerance and effectiveness in metastatic renal cell cancer
(Dartmouth-Hitchcock Medical Center) A novel combination of nivolumab plus ipilimumab for patients with metastatic kidney cancer is proving to be a more effective treatment with more durable tumor response than the two immunotherapies used separately. The promising combination therapy demonstrated manageable safety, notable antitumor activity, and durable responses with better long term overall survival in patients with metastatic renal cell cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 26, 2017 Category: International Medicine & Public Health Source Type: news

Immune Checkpoint Inhibitors Effective for Advanced Urothelial, Renal Cancers Immune Checkpoint Inhibitors Effective for Advanced Urothelial, Renal Cancers
In patients with advanced urothelial cell and renal cell cancers, immune checkpoint inhibitors (ICIs) are more effective and safer than conventional second-line treatment, a new systematic review from The Netherlands reports.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 18, 2017 Category: Pathology Tags: Hematology-Oncology News Source Type: news

EUSA Pharma Receives Positive CHMP Opinion for Tivozanib
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of FOTIVDA ® (tivozanib) for the management of adult patients with advanced renal cell carcinoma (RCC). EUSA's marketing authorisation application included data from the TiVO-1 pivotal study, which included over 500 patients with advanced RCC.07/12/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 12, 2017 Category: Urology & Nephrology Source Type: news

Exelixis and BMS start Phase III combination trial for renal cell carcinoma
Exelixis and Bristol-Myers Squibb (BMS) have started the Phase III CheckMate 9ER clinical trial of Cabometyx (cabozantinib) combined with Opdivo (nivolumab) or both Opdivo and Yervoy (ipilimumab) to treat renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - July 10, 2017 Category: Pharmaceuticals Source Type: news

Savolitinib Active in MET-Driven Advanced Papillary RCC
A phase II study has shown that savolitinib is active in a subgroup of patients with papillary renal cell carcinoma with gene amplification or mutations in the MET pathway. (Source: CancerNetwork)
Source: CancerNetwork - July 6, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Renal Cell Carcinoma Source Type: news

Targeting Genetic Drivers of Rare Genitourinary Cancers
This video reviews new studies examining the genetic drivers of three rare genitourinary cancers: von Hippel-Lindau disease, advanced papillary renal cell carcinoma, and penile cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 5, 2017 Category: Cancer & Oncology Authors: Guru Sonpavde, MD Tags: Videos Genitourinary Cancers Source Type: news

AstraZeneca and Chi-Med begin Phase III trial of savolitinib for PRCC
AstraZeneca and Hutchison China MediTech (Chi-Med) have started a Phase III SAVOIR clinical trial of savolitinib to treat patients with papillary renal cell carcinoma (PRCC). (Source: Drug Development Technology)
Source: Drug Development Technology - June 29, 2017 Category: Pharmaceuticals Source Type: news

Physical Inactivity Linked to Kidney, Bladder Cancers
Lack of participation in any regular recreational physical activity was associated with a significantly increased risk for both bladder and renal cancers. (Source: CancerNetwork)
Source: CancerNetwork - June 29, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Bladder Cancer News Renal Cell Carcinoma Source Type: news

Could SBRT Have Role in Metastatic Kidney Cancer?
This video examines a pilot trial that tested stereotactic body radiotherapy plus nephrectomy in patients with renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 28, 2017 Category: Cancer & Oncology Authors: Thomas Schwaab, MD, PhD Tags: News Renal Cell Carcinoma Videos Genitourinary Cancers Source Type: news

EMA Panel Likes Breast and Kidney Cancer Drugs EMA Panel Likes Breast and Kidney Cancer Drugs
The Committee for Medicinal Products for Human Use recommended approval of ribociclib for advanced HER+/HER2- breast cancer and tivozanib for advanced renal cell carcinoma.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for the First-Line Treatment of Advanced Renal Cell Carcinoma in Europe
HEMEL HEMPSTEAD, England, June 23, 2017 -- (Healthcare Sales & Marketing Network) -- EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced that the European Medicines Agency's Committ... Biopharmaceuticals, Oncology, Regulatory EUSA Pharma, FOTIVDA, tivozanib, renal cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 23, 2017 Category: Pharmaceuticals Source Type: news

Considering a Clinical Trial? Phase II Clinical Study of Lenvatinib
Eisai announced today the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma.06/17/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 17, 2017 Category: Urology & Nephrology Source Type: news

Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth
The mechanistic target of rapamycin complex 1 (mTORC1) is recruited to the lysosome by Rag guanosine triphosphatases (GTPases) and regulates anabolic pathways in response to nutrients. We found that MiT/TFE transcription factors—master regulators of lysosomal and melanosomal biogenesis and autophagy—control mTORC1 lysosomal recruitment and activity by directly regulating the expression of RagD. In mice, this mechanism mediated adaptation to food availability after starvation and physical exercise and played an important role in cancer growth. Up-regulation of MiT/TFE genes in cells and tissues from patients and...
Source: ScienceNOW - June 15, 2017 Category: Science Authors: Di Malta, C., Siciliano, D., Calcagni, A., Monfregola, J., Punzi, S., Pastore, N., Eastes, A. N., Davis, O., De Cegli, R., Zampelli, A., Di Giovannantonio, L. G., Nusco, E., Platt, N., Guida, A., Ogmundsdottir, M. H., Lanfrancone, L., Perera, R. M., Zoncu Tags: Genetics reports Source Type: news

Epacadostat Plus Pembrolizumab Shows Early Promise in Advanced RCC
Epacadostat plus pembrolizumab yielded “encouraging response outcomes” among patients with 0 or 1 prior lines of therapy for advanced renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: News Renal Cell Carcinoma Source Type: news

16-Gene Recurrence Score for High-Risk RCC Offers Prognostic Value
Analysis from a phase III trial confirmed the prognostic value of a 16-gene recurrence score in patients with high-risk renal cell carcinoma undergoing adjuvant sunitinib therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Conferences/ASCO Renal Cell Carcinoma News Source Type: news

Aveo Oncology ’s tivozanib enters Phase II part of TiNivo trial for RCC
US-based biopharmaceutical firm Aveo Oncology ’s oral drug candidate tivozanib has advanced into the Phase II part of the Phase I/II TiNivo clinical trial to treat advanced renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - June 8, 2017 Category: Pharmaceuticals Source Type: news

Pazopanib Not Recommended as Adjuvant Therapy of Locally Advanced RCC
Pazopanib 600 mg daily as adjuvant therapy did not prolong disease-free survival for patients with locally advanced renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Renal Cell Carcinoma News Source Type: news

Atezolizumab/Bevacizumab in Metastatic RCC Moves to Phase III Trial
This video reviews second-line data from the IMmotion150 trial, which initially studied atezolizumab with or without bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma patients. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2017 Category: Cancer & Oncology Authors: Michael B. Atkins, MD Tags: Conferences/ASCO Renal Cell Carcinoma News Videos Genitourinary Cancers Source Type: news

Pembrolizumab Plus Pazopanib Is Not Safe for Patients with RCC
Liver toxicity precludes development of pembrolizumab plus pazopanib immunotherapy for patients with advanced renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Renal Cell Carcinoma News Source Type: news

First-Line Avelumab/Axitinib Shows Early Antitumor Activity in mRCC
Despite high rates of toxicity, a first-line tyrosine kinase inhibitor/immunotherapy combination exhibits promising antitumor activity in metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Conferences/ASCO Renal Cell Carcinoma Genitourinary Cancers News Source Type: news

Biomarkers Predict RCC Treatment Outcomes
Plasma levels of HGF, BAP1 and PBRM1 gene mutation status, and angiogenesis gene expression are promising predictive biomarkers for survival in RCC patients. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Renal Cell Carcinoma News Source Type: news

Clinicians Must Tailor Treatment for Metastatic RCC
In this interview we discuss decision making in the treatment of metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2017 Category: Cancer & Oncology Authors: Neeraj Agarwal, MD Tags: Conferences/ASCO Renal Cell Carcinoma Genitourinary Cancers Q & Source Type: news

Individualized Sunitinib Dosing Improves Response, Survival in RCC
Individualizing first-line sunitinib was associated with improved response and survival times among patients with metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Renal Cell Carcinoma News Source Type: news

X4 Pharmaceuticals begins Phase II trial of X4P-001 to treat ccRCC
US-based biotechnology firm X4 Pharmaceuticals has begun the Phase II portion of its ongoing Phase I/II clinical trial with dosing of X4P-001 in combination with Inlyta (axitinib) in advanced clear cell renal cell carcinoma (ccRCC) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - May 25, 2017 Category: Pharmaceuticals Source Type: news

@FDA_Patient_Net seeks advocates who have experience with renal cell carcinoma. For more information go to http://go.usa.gov/x9hCY   #cancerpic.twitter.com/6l58hzi46E
@FDA_Patient_Net seeks advocates who have experience with renal cell carcinoma. For more information go to http://go.usa.gov/x9hCY  #cancer pic.twitter.com/6l58hzi46E (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - May 25, 2017 Category: Medical Devices Authors: ( at FDA_Patient_Net) Source Type: news

Phase 2 Study Comparing CB-839 With Everolimus vs. Placebo With Everolimus
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)05/25/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 25, 2017 Category: Urology & Nephrology Source Type: news

Phase 2/3 Trial of Abexinostat In Renal Cell Carcinoma
Xynomic Pharma, a clinical stage US oncology drug R&D company, today announced that it has entered into a strategic partnership with the University of California San Francisco ("UCSF") to conduct PAX Study, a multi-national, multi-center, randomized Phase 2/3 study of Pazopanib plus Abexinostat versus Pazopanib monotherapy in patients with locally advanced or metastatic renal cell carcinoma ("RCC").05/23/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 23, 2017 Category: Urology & Nephrology Source Type: news